Cardiovascular Disease Clinical Trial
Official title:
A Phase I, Open-Label, Single-Period Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolite Profile and Metabolite Identification After Oral Administration of [14C]AZD4831 in Healthy Male Subjects
The Sponsor is developing the test medicine, AZD4831, for the potential treatment of
cardiovascular disease (CVD). CVD is a general term to describe a range of conditions that
affect the heart and blood vessels, examples of CVD include angina (chest pain caused by
restricted blood flow to heart muscle) and heart failure (where the heart is unable to pump
blood around the body properly). AZD4831 is an inhibitor of a protein that has a role in the
formation of fatty deposits in arteries (blood vessels that take blood to the body). It is
hoped that by inhibiting this action, AZD4831 will help with the management of CVD.
The study involves radiolabelling (labelling the molecule with radioactive 14C) which is used
to locate the molecule within the body. The study will try to assess how much radioactivity
can be recovered from the urine and faeces (mass balance recovery) after a single oral dose
of [14C]AZD4831. It will also look to identify the breakdown products (metabolites) of the
parent drug. It will additionally determine the rate and route of elimination of
[14C]AZD4831, along with the level of test medicine in the blood. The safety and tolerability
of the test medicine will be assessed. The dose of radiation administered is very low,
therefore the risk associated with this is very small.
The study will consist of a single study period involving up to six healthy male volunteers.
Up to six male volunteers will receive a dose of 10 mg of the radiolabelled test medicine as
an oral solution. Blood, urine and faecal samples will be collected from volunteers whilst
they are resident in the clinical unit for up to 336 hours post-dose (Day 15). A follow-up
visit will take place seven to ten days after discharge for safety assessments.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02122198 -
Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women
|
N/A | |
| Completed |
NCT02502812 -
Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT04216342 -
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT03654313 -
Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus
|
Phase 1 | |
| Completed |
NCT03646656 -
Heart Health Buddies: Peer Support to Decrease CVD Risk
|
N/A | |
| Completed |
NCT02081066 -
Identification of CETP as a Marker of Atherosclerosis
|
N/A | |
| Completed |
NCT02147626 -
Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia
|
N/A | |
| Not yet recruiting |
NCT06405880 -
Pharmacist Case Finding and Intervention for Vascular Prevention Trial
|
N/A | |
| Recruiting |
NCT03095261 -
Incentives in Cardiac Rehabilitation
|
N/A | |
| Completed |
NCT02998918 -
Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL
|
N/A | |
| Not yet recruiting |
NCT02578355 -
National Plaque Registry and Database
|
N/A | |
| Completed |
NCT02868710 -
Individual Variability to Aerobic Exercise Training
|
N/A | |
| Completed |
NCT02589769 -
Effects of Reduction in Saturated Fat on Cholesterol and Lipoproteins in Lean and Obese Persons
|
N/A | |
| Completed |
NCT02711878 -
Healing Hearts and Mending Minds in Older Adults Living With HIV
|
N/A | |
| Recruiting |
NCT02885792 -
Coronary Artery Disease in Patients Suffering From Schizophrenia
|
N/A | |
| Completed |
NCT02657382 -
Mental Stress Ischemia: Biofeedback Study
|
N/A | |
| Completed |
NCT02640859 -
Investigation of Metabolic Risk in Korean Adults
|
||
| Completed |
NCT02652975 -
Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium
|
N/A | |
| Completed |
NCT02272946 -
Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk
|
Phase 2 | |
| Recruiting |
NCT02265250 -
Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment
|